Skip to main content
SpringerLink
Log in

La gestione degli effetti collaterali della terapia con farmaci inibitori delle tirosino-chinasi

  • ONCOLOGIA TIROIDEA
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Resteghini C, Cavalieri S, Galbiati D et al. (2017) Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res, Clin Endocrinol Metab 31(3):349–361

    Article  CAS  Google Scholar 

  2. Capdevila J, Newbold K, Licitra L et al. (2018) Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 69:164–176

    Article  CAS  Google Scholar 

  3. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Updated November 27, 2017. Accessed July 17, 2018

  4. Elisei R, Trimarchi F (2017) Comunicare con la persona con cancro della tiroide in progressione. Endocrinologo 18:224–230

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UO Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia

    Virginia Cappagli & Eleonora Molinaro

Authors
  1. Virginia Cappagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleonora Molinaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleonora Molinaro.

Ethics declarations

Conflitto di interesse

Le autrici Virginia Cappagli e Eleonora Molinaro dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Le autrici di questo articolo non hanno eseguito studi sugli animali.

Additional information

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cappagli, V., Molinaro, E. La gestione degli effetti collaterali della terapia con farmaci inibitori delle tirosino-chinasi. L'Endocrinologo 21 (Suppl 1), 36–38 (2020). https://doi.org/10.1007/s40619-020-00703-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-020-00703-5

Search

Navigation